BC
VIR icon

Brookfield Corp’s Vir Biotechnology VIR Stock Holding History

Brookfield Corp’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-84,444
Closed -$2.15M – 777
2022
Q2 		$2.15M Sell
84,444
-556
-0.7% -$13K 0.01% 400
2022
Q1 		$2.19M Sell
85,000
-22,500
-21% -$667K 0.01% 381
2021
Q4 		$4.5M Buy
+107,500
New +$4.21M 0.02% 233

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brookfield Corp's VIR Position: Q3 2022 in Review

Brookfield Corp sold out of Vir Biotechnology (VIR) in Q3 2022, closing a stake of 84,444 shares — an estimated $2.15M sold.

Brookfield Corp first reported a position in VIR in Q4 2021 and held it in 3 quarters. The position peaked at $4.5M in Q4 2021. 221 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

  • Brookfield Corp reported no remaining Vir Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Brookfield Corp sold 84,444 Vir Biotechnology shares in Q3 2022, an estimated $2.15M.
  • Brookfield Corp first reported a position in Vir Biotechnology in Q4 2021 and held it in 3 quarters.
  • Brookfield Corp's Vir Biotechnology position peaked at $4.5M in Q4 2021.
  • 221 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on Brookfield Corp's 13F filing for Q3 2022, filed 14 Nov 2022.